Merck's Keytruda Dependency Gets Its Most Important Quarterly Stress Test Yet

Merck & Company (MRK) reports first-quarter 2026 earnings before market open on April 30, with Wall Street bracing for an unprecedented loss driven by one-time charges rather than operational deterioration. The pharmaceutical giant faces a critical test: can management reassure investors that the company's core business remains intact despite a -$1.51 per share consensus estimate—a dramatic reversal from four consecutive quarters of profitability? With the stock trading below most key moving averages and technical momentum weakening sharply, this earnings release will determine whether investors view the quarter as a temporary accounting blip or the start of deeper concerns.

Part 1: Earnings Preview

Merck & Company is a global pharmaceutical leader focused on prescription medicines, vaccines, and animal health products, with blockbuster franchises including Keytruda (cancer immunotherapy), Gardasil (HPV vaccine), and a growing portfolio of specialty therapeutics that generate over $65 billion in annual revenue.

Merck reports first-quarter results before market open on April 30, with analysts expecting a loss of -$1.51 per share on revenue of approximately $15.85 billion. The company most recently reported fourth-quarter 2025 earnings of $2.04 per share, marking its fourth consecutive quarterly beat. Comparing to the same quarter last year, when Merck earned $2.22 per share, the year-over-year decline of -168% reflects significant one-time charges rather than business fundamentals—a critical distinction investors must parse.

Three key themes define this earnings story:

Acquisition-Related Charges vs. Core Performance: The negative EPS estimate stems primarily from the $9 billion upfront charge related to Merck's acquisition of Sidera Therapeutics, announced in February 2026. Management has guided that excluding this non-deductible charge and ongoing transaction costs (totaling approximately $3.65 per share), adjusted EPS would approach $9.03 for the full year. Investors will scrutinize whether the company can clearly separate these accounting impacts from operational results and demonstrate that underlying business momentum remains strong. The revenue estimate of $15.85 billion—roughly in line with recent quarters—suggests the core pharmaceutical business continues performing steadily despite the headline loss.

Pipeline Expansion and Long-Term Growth Trajectory: Merck has significantly expanded its commercial opportunity outlook, with management citing line of sight to over $70 billion in potential revenue by the mid-2030s—more than double consensus 2028 Keytruda peak estimates. The company identified 21 potential new growth drivers in its February call, with 10 expected to be substantially de-risked clinically over the next two years. Key near-term catalysts include regulatory decisions on HIV candidate islotrovir, multiple Keytruda label expansions, and Phase III readouts for cardiovascular asset enlicitide. Investors will look for updates on these pipeline programs and any new data supporting the aggressive long-term growth thesis, particularly as Keytruda faces eventual loss of exclusivity pressures.

Vaccine Headwinds and Pricing Pressures: The company faces meaningful near-term challenges beyond the acquisition charge, including a 35% decline in Gardasil sales during Q4 2025 and slower-than-expected uptake of its RSV vaccine. Management has identified approximately $2.5 billion in headwinds from generic competition, IRA price-setting provisions, and a restructured Koselugo agreement. With 2026 full-year guidance calling for just 1-3% revenue growth (including a 1-percentage-point FX benefit), investors will focus on whether vaccine weakness is stabilizing and how the company plans to offset pricing pressures through volume growth and new product launches like Winrevair and Capvaxive.

Leading analysts maintain a constructive stance despite near-term noise. The 17 Strong Buy ratings among 28 analysts covering the stock reflect confidence that current challenges are transitory, with the $131.92 average price target implying nearly 19% upside. However, the sharp deterioration in Barchart's Technical Opinion—from 96% Buy a month ago to just 24% Buy currently—suggests growing investor caution heading into the print. Analysts will listen closely for management's tone on whether the business inflection expected in 2027 (with 101% EPS growth forecast) remains achievable.

Part 2: Historical Earnings Performance

Merck has established a consistent pattern of exceeding Wall Street's earnings expectations, beating estimates in each of the past four quarters. The company's most recent beat in Q4 2025 was modest at +0.49%, but the three quarters prior showed accelerating positive surprises: +3.26% in Q1 2025, +5.97% in Q2 2025, and a particularly strong +9.32% in Q3 2025. This track record demonstrates management's ability to guide conservatively and deliver upside, building credibility with investors.

The magnitude of beats has been meaningful in absolute terms as well, ranging from $0.01 to $0.22 per share above consensus. Reported EPS remained remarkably stable across 2025, fluctuating between $2.04 and $2.58 despite the typical seasonality in pharmaceutical sales. This consistency reflects the diversified nature of Merck's revenue base across oncology, vaccines, and animal health, which helps smooth quarterly volatility.

The upcoming quarter breaks sharply from this pattern, with the -$1.51 estimate representing a loss rather than profit. However, this departure is driven entirely by the $9 billion Sidera acquisition charge rather than operational deterioration. Investors should focus on adjusted earnings metrics, which exclude one-time items—Merck's history of beating on operational performance suggests the core business likely remains on track despite the headline loss.

Note: These figures reflect diluted GAAP earnings per share, reported before non-recurring items, and may differ from the non-GAAP figures used by some sources.

Part 2.1: Price Behavior Around Earnings

Merck typically reports earnings before market open, meaning Day 0 represents the first full trading session where investors react to results, while Day +1 captures follow-through momentum.

Historical price behavior shows Merck experiences moderate volatility around earnings, with an average absolute Day 0 move of 3.73% and Day 0 range of 5.32%. The Day +1 follow-through is typically more subdued, averaging 1.38% with a 3.17% range, suggesting most of the price discovery occurs in the immediate reaction session.

The direction of moves has been mixed, with the most recent February 2026 report producing a +2.18% Day 0 gain followed by +2.15% on Day +1—a rare instance of sustained positive momentum. However, the prior two reports in October and July 2025 saw modest declines or minimal movement, indicating investors have been cautious despite the company's consistent earnings beats. The largest moves occurred in February and July 2024, when the stock dropped -9.07% and -9.81% respectively on Day 0, demonstrating that Merck can experience sharp reactions when results or guidance disappoint.

Given the unusual nature of this quarter's expected loss, historical patterns may be less predictive than usual. Investors should prepare for elevated volatility as the market digests whether management can effectively communicate that underlying business trends remain healthy despite the accounting charge.

Part 2.2: Options Market Expected Move

The options market is pricing an expected move of 3.91% for this earnings release, which sits slightly above the 3.73% average absolute Day 0 move but below the 5.32% average Day 0 range observed historically. This suggests options traders are anticipating moderate volatility—recognizing the unusual nature of the expected loss but not pricing in an extreme reaction, likely because the one-time charge has been well-telegraphed since the February guidance.

Part 3: What Analysts Are Saying

Analysts maintain a bullish stance on Merck heading into earnings, with a consensus rating of 4.29 on the 5-point scale—firmly in Buy territory. The average price target of $131.92 implies approximately 18.9% upside from the current price of $110.95, with the range of estimates spanning from $100.00 on the low end to $150.00 on the high end. This wide target range reflects differing views on how quickly Merck can return to robust earnings growth following the 2026 transition year.

The rating breakdown shows strong conviction, with 17 Strong Buy ratings and 2 Moderate Buy ratings among the 28 analysts covering the stock, while 9 analysts recommend Hold and zero rate it a Sell. This 68% buy-side representation demonstrates broad confidence that current headwinds are temporary and the stock offers attractive value at current levels, particularly given the company's expanded pipeline and long-term commercial opportunity approaching $70 billion by the mid-2030s.

Analyst sentiment has remained unchanged over the past month despite the stock's recent weakness, suggesting the sell-side views the technical deterioration as a buying opportunity rather than a signal of fundamental concerns. The stability in ratings indicates analysts are looking through the near-term accounting noise to focus on 2027 and beyond, when consensus expects EPS to rebound sharply to $9.85—representing 101% growth from the depressed 2026 base of $4.89.

Part 4: Technical Picture

Merck's technical setup heading into earnings has deteriorated significantly, with the Barchart Technical Opinion weakening from 96% Buy a month ago to 56% Buy last week and now just 24% Buy currently. This sharp decline in technical momentum suggests growing investor caution and profit-taking ahead of the unusual quarterly loss, even as the sell-side maintains bullish fundamental views.

Timeframe Analysis:

• Short-term (Hold): Neutral signal indicates near-term momentum has stalled as investors await clarity on the earnings report
• Medium-term (50% Buy): Moderate buy signal suggests the intermediate trend remains constructive despite recent weakness
• Long-term (50% Buy): Moderate buy signal reflects the stock's position above the 200-day moving average, indicating the longer-term uptrend remains intact

The trend is characterized as Soft in strength with the Weakest directional momentum, indicating the technical environment is fragile heading into this earnings release.

The stock currently trades at $110.95, positioned below the 5-day ($111.55), 10-day ($113.48), 20-day ($117.10), and 50-day ($117.98) moving averages, but remains above the critical 200-day moving average at $99.61. This configuration shows Merck in a short-term downtrend within a longer-term uptrend—a classic consolidation pattern that could resolve in either direction based on the earnings reaction.

The 100-day moving average at $113.18 represents immediate overhead resistance, while the 200-day average at $99.61 provides crucial support roughly 11% below current levels. The stock's position below all short- and intermediate-term moving averages suggests limited technical momentum heading into the print, meaning a positive surprise on adjusted earnings or encouraging guidance could trigger a sharp relief rally back toward the $117-118 resistance zone. Conversely, any disappointment in core business trends could accelerate the recent downtrend. The overall technical setup is cautionary, with the burden on management to deliver a clear, confidence-building message that separates accounting noise from operational reality.